Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand across Canada, the U.S., and Asia. While the company boasts a strong gross margin of 70.5%, it faces significant concerns with negative EBITDA and net margins of -36.8% and -42.5%, respectively, indicating operational inefficiencies. Additionally, a current and quick ratio of 0.02 raises liquidity concerns, suggesting potential difficulties in meeting short-term obligations. The high gross margin juxtaposed with poor overall profitability highlights a troubling disconnect in financial performance.
Loading financial metrics...
Company posted a loss of $-333K over the last year, representing 42.5% of revenue.
Debt of $78K is 4.4x the company's cash position of $18K.
Revenue growing at 11.4% YoY, outpacing typical market growth rates.
Gross margin expanded by 13.3 percentage points, indicating improved pricing power or cost efficiency.
Operating margin expanded by 19.8pp, demonstrating strong operational leverage.
Both gross margin (+13.3pp) and operating margin (+19.8pp) are expanding simultaneously, indicating the company is scaling profitably.
Exceptional gross margin of 70.5% indicates strong pricing power and competitive moat.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Food Distribution companies of a similar size
Based on 2025-FY (October 31, 2025)